Mylan Pharmaceuticals Inc
- All
- News
-
US Patents rejects Teva's plea on Copaxone; Natco shares up
The United States Patent and Trademark Office (the "PTO") issued a final office action rejecting Teva's application seeking a reissue of US Patent No. 5,800,808 (the "'808 Patent"), which was found to be invalid by the Court of Appeals for the Federal Circuit in July 2013
-
US Supreme Court agrees to hear Tevas pharma's appeal
Last year, US Court of Appeals for the Federal Circuit reversed a district court's earlier finding related to Teva's US Patent for the drug.
-
GlaxoSmithKline's Rs 6,400-crore FDI proposal cleared by investment board: report
The Singapore subsidiary of the UK-based GlaxoSmithKline plans to buy 24.33 per cent stake or 2.06 crore equity shares in GlaxoSmithKline Pharmaceuticals Ltd through an open offer.
-
Mylan's Rs 5,168 crore deal to buy Strides unit gets cabinet nod
The acquisition, however, is subject to certain conditions. After the completion of the acquisition process, Mylan has to maintain the investment level in R&D in value terms for five years at absolute quantitative level at the time of induction of FDI, according to sources.
-
Pfizer files patent suit against Lupin, 5 other pharma firms
US-based pharma giant Pfizer Inc today said it has filed suit against six firms, including India's Lupin, over patent infringement of celecoxib, the active ingredient of its branded drug Celebrex used for treating osteoarthritis.
-
US Patents rejects Teva's plea on Copaxone; Natco shares up
The United States Patent and Trademark Office (the "PTO") issued a final office action rejecting Teva's application seeking a reissue of US Patent No. 5,800,808 (the "'808 Patent"), which was found to be invalid by the Court of Appeals for the Federal Circuit in July 2013
-
US Supreme Court agrees to hear Tevas pharma's appeal
Last year, US Court of Appeals for the Federal Circuit reversed a district court's earlier finding related to Teva's US Patent for the drug.
-
GlaxoSmithKline's Rs 6,400-crore FDI proposal cleared by investment board: report
The Singapore subsidiary of the UK-based GlaxoSmithKline plans to buy 24.33 per cent stake or 2.06 crore equity shares in GlaxoSmithKline Pharmaceuticals Ltd through an open offer.
-
Mylan's Rs 5,168 crore deal to buy Strides unit gets cabinet nod
The acquisition, however, is subject to certain conditions. After the completion of the acquisition process, Mylan has to maintain the investment level in R&D in value terms for five years at absolute quantitative level at the time of induction of FDI, according to sources.
-
Pfizer files patent suit against Lupin, 5 other pharma firms
US-based pharma giant Pfizer Inc today said it has filed suit against six firms, including India's Lupin, over patent infringement of celecoxib, the active ingredient of its branded drug Celebrex used for treating osteoarthritis.
